A new cellular model to follow Friedreich's ataxia development in a time-resolved way

DMM Disease Models and Mechanisms

Volumn 8, Issue 7, 2015, Pages 711-719

  Vannocci, Tommaso ^a   Faggianelli, Nathalie ^a   Zaccagnino, Silvia ^a   Della Rosa, Ilaria ^a   Adinolfi, Salvatore ^b   Pastore, Annalisa ^b  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cellular model; Disease development; Frataxin; Genetic models; Zinc fingers

Indexed keywords

FRATAXIN; DNA; IRON BINDING PROTEIN;

ARTICLE; CELL ENGINEERING; CELL LINE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DISEASE COURSE; FRIEDREICH ATAXIA; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; WESTERN BLOTTING; BIOLOGICAL MODEL; GENE INACTIVATION; GENETIC ENGINEERING; GENETICS; HEK293 CELL LINE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

PRIMATES;

BASE SEQUENCE; CELL LINE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; DISEASE PROGRESSION; DNA; FRIEDREICH ATAXIA; GENE KNOCKOUT TECHNIQUES; GENETIC ENGINEERING; HEK293 CELLS; HUMANS; IRON-BINDING PROTEINS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; TRANSFECTION;

EID: 84937958039     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.020545     Document Type: Article

References (46)

1. Albrecht, S. C., Sobotta, M. C., Bausewein, D., Aller, I., Hell, R., Dick, T. P. and Meyer, A. J. (2014). Redesign of genetically encoded biosensors for monitoring mitochondrial redox status in a broad range of model eukaryotes. J. Biomol. Screen. 19, 379-386.
2. Al-Mahdawi, S., Pinto, R. M., Ismail, O., Varshney, D., Lymperi, S., Sandi, C., Trabzuni, D. and Pook, M. (2008). The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum. Mol. Genet. 17, 735-746.
3. Anderson, P. R., Kirby, K., Hilliker, A. J. and Phillips, J. P. (2005). RNAi-mediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum. Mol. Genet. 14, 3397-3405.
4. Bedell, V. M., Wang, Y., Campbell, J. M., Poshusta, T. L., Starker, C. G., Krug, R. G., II, Tan, W., Penheiter, S. G., Ma, A. C., Leung, A. Y. H. et al. (2012). In vivo genome editing using a high-efficiency TALEN system. Nature 491, 114-118.
5. Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., Lahaye, T., Nickstadt, A. and Bonas, U. (2009). Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326, 1509-1512.
6. Calmels, N., Schmucker, S., Wattenhofer-Donzé, M., Martelli, A., Vaucamps, N., Reutenauer, L., Messaddeq, N., Bouton, C., Koenig, M. and Puccio, H. (2009). The first cellular models based on frataxin missense mutations that reproduce spontaneously the defects associated with Friedreich ataxia. PLoS ONE 4, e6379.
7. Campuzano, V., Montermini, L., Molto, M. D., Pianese, L., Cossée, M., Cavalcanti, F., Monros, E., Rodius, F., Duclos, F., Monticelli, A. et al. (1996). Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423-1427.
8. Carlson, D. F., Tan, W., Lillico, S. G., Stverakova, D., Proudfoot, C., Christian, M., Voytas, D. F., Long, C. R., Whitelaw, C. B. A. and Fahrenkrug, S. C. (2012). Efficient TALEN-mediated gene knockout in livestock. Proc. Natl. Acad. Sci. USA 109, 17382-17387.
9. Cermak, T., Doyle, E. L., Christian, M., Wang, L., Zhang, Y., Schmidt, C., Baller, J. A., Somia, N. V., Bogdanove, A. J. and Voytas, D. F. (2011). Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39, e82.
10. Cossée, M., Schmitt, M., Campuzano, V., Reutenauer, L., Moutou, C., Mandel, J.-L. and Koenig, M. (1997). Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc. Natl. Acad. Sci. USA 94, 7452-7457.
11. Cossée, M., Durr, A., Schmitt, M., Dahl, N., Trouillas, P., Allinson, P., Kostrzewa, M., Nivelon-Chevallier, A., Gustavson, K.-H., Kohlschutter, A. et al. (1999). Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann. Neurol. 45, 200-206.
12. Cossée, M., Puccio, H., Gansmuller, A., Koutnikova, H., Dierich, A., LeMeur, M., Fischbeck, K., Dolle, P. and Koenig, M. (2000). Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum. Mol. Genet. 9, 1219-1226.
13. Dahlem, T. J., Hoshijima, K., Jurynec, M. J., Gunther, D., Starker, C. G., Locke, A. S., Weis, A. M., Voytas, D. F. and Grunwald, D. J. (2012). Simple methods for generating and detecting locus-specific mutations induced with TALENs in the zebrafish genome. PLoS Genet. 8, e1002861.
14. Doyle, E. L., Booher, N. J., Standage, D. S., Voytas, D. F., Brendel, V. P., VanDyk, J. K. and Bogdanove, A. J. (2012). TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res. 40, W117-W122.
15. Doyon, Y., Vo, T. D., Mendel, M. C., Greenberg, S. G., Wang, J., Xia, D. F., Miller, J. C., Urnov, F. D., Gregory, P. D. and Holmes, M. C. (2011). Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat. Methods 8, 74-79.
16. Filla, A., De Michele, G., Cavalcanti, F., Pianese, L., Monticelli, A., Campanella, G. and Cocozza, S. (1996). The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am. J. Hum. Genet. 59, 554-560.
17. Gaj, T., Gersbach, C. A. and Barbas, C. F.III. (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397-405.
18. Hacein-Bey-Abina, S., Hauer, J., Lim, A., Picard, C., Wang, G. P., Berry, C. C., Martinache, C., Rieux-Laucat, F., Latour, S., Belohradsky, B. H. et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363, 355-364.
19. Hick, A., Wattenhofer-Donze, M., Chintawar, S., Tropel, P., Simard, J. P., Vaucamps, N., Gall, D., Lambot, L., Andre, C., Reutenauer, L. et al. (2013). Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxia. Dis. Model. Mech. 6, 608-621.
20. Horvath, P. and Barrangou, R. (2010). CRISPR/Cas, the immune system of bacteria and archaea. Science 327, 167-170.
21. Ku, S., Soragni, E., Campau, E., Thomas, E. A., Altun, G., Laurent, L. C., Loring, J. F., Napierala, M. and Gottesfeld, J. M. (2010). Friedreich's ataxia induced pluripotent stem cells model intergenerational GAA·TTC triplet repeat instability. Cell Stem Cell 7, 631-637.
22. Llorens, J. V., Navarro, J. A., Martinez-Sebastian, M. J., Baylies, M. K., Schneuwly, S., Botella, J. A. and Molto, M. D. (2007). Causative role of oxidative stress in a Drosophila model of Friedreich ataxia. FASEB J. 21, 333-344.
23. Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E. and Church, G. M. (2013). RNA-guided human genome engineering via Cas9. Science 339, 823-826.
24. Martelli, A. and Puccio, H. (2014). Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation. Frontier. Pharmacol. 5, 130.
25. Martelli, A., Napierala, M. and Puccio, H. (2012). Understanding the genetic and molecular pathogenesis of Friedreich's ataxia through animal and cellular models. Dis. Model. Mech. 5, 165-176.
26. Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J. et al. (2011). A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143-148.
27. Muhlenhoff, U., Richhardt, N., Ristow, M., Kispal, G. and Lill, R. (2002). The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum. Mol. Genet. 11, 2025-2036.
28. Mussolino, C., Morbitzer, R., Lutge, F., Dannemann, N., Lahaye, T. and Cathomen, T. (2011). A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 39, 9283-9293.
29. Nemudryi, A. A., Valetdinova, K. R., Medvedev, S. P. and Zakian, S. M. (2014). TALEN and CRISPR/Cas genome editing systems: tools of discovery. Acta Naturae 6, 19-40.
30. Pandolfo, M. (2009). Friedreich ataxia: the clinical picture. J. Neurol. 256 Suppl. 1, 3-8.
31. Pandolfo, M. and Pastore, A. (2009). The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J. Neurol. 256 Suppl. 1, 9-17.
32. Pastore, A. and Adinolfi, S. (2014). Chronochemistry in neurodegeneration. Frontier. Mol. Neurosci. 7, 20.
33. Pastore, A. and Puccio, H. (2013). Frataxin: a protein in search for a function. J. Neurochem. 126 Suppl. 1, 43-52.
34. Perdomini, M., Hick, A., Puccio, H. and Pook, M. A. (2013). Animal and cellular models of Friedreich ataxia. J. Neurochem. 126 Suppl. 1, 65-79.
35. Pook, M. A., Al-Mahdawi, S., Carroll, C. J., Cossée, M., Puccio, H., Lawrence, L., Clark, P., Lowrie, M. B., Bradley, J. L., Cooper, J. M. et al. (2001). Rescue of the Friedreich's ataxia knockout mouse by human YAC transgenesis. Neurogenetics 3, 185-193.
36. Puccio, H., Simon, D., Cossée, M., Criqui-Filipe, P., Tiziano, F., Melki, J., Hindelang, C., Matyas, R., Rustin, P. and Koenig, M. (2001). Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 27, 181-186.
37. Sandi, C., Al-Mahdawi, S. and Pook, M. A. (2013). Epigenetics in Friedreich's ataxia: challenges and opportunities for therapy. Genet. Res. Int. 2013, 852080.
38. Saveliev, A., Everett, C., Sharpe, T., Webster, Z. and Festenstein, R. (2003). DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 422, 909-913.
39. Schmucker, S., Argentini, M., Carelle-Calmels, N., Martelli, A. and Puccio, H. (2008). The in vivo mitochondrial two-step maturation of human frataxin. Hum. Mol. Genet. 17, 3521-3531.
40. Simon, D., Seznec, H., Gansmuller, A., Carelle, N., Weber, P., Metzger, D., Rustin, P., Koenig, M. and Puccio, H. (2004). Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. J. Neurosci. 24, 1987-1995.
41. Thomas, K. R. and Capecchi, M. R. (1987). Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51, 503-512.
42. Thomas, K. R., Folger, K. R. and Capecchi, M. R. (1986). High frequency targeting of genes to specific sites in the mammalian genome. Cell 44, 419-428.
43. Vaubel, R. A. and Isaya, G. (2013). Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia. Mol.Cell. Neurosci. 55, 50-61.
44. Wright, D. A., Thibodeau-Beganny, S., Sander, J. D., Winfrey, R. J., Hirsh, A. S., Eichtinger, M., Fu, F., Porteus, M. H., Dobbs, D., Voytas, D. F. et al. (2006). Standardized reagents and protocols for engineering zinc finger nucleases by modular assembly. Nat. Protoc. 1, 1637-1652.
45. Yanez, R. J. and Porter, A. C. G. (1998). Therapeutic gene targeting. Gene Ther. 5, 149-159.
46. Yao, F., Svensjö, T., Winkler, T., Lu, M., Eriksson, C. and Eriksson, E. (1998). Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum. Gene Ther. 9, 1939-1950.